Common use of Implementation Report Clause in Contracts

Implementation Report. Within 120 days after the Effective Date, RMC shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 2. the names and positions of the members of the Compliance Committee required by Section III.A; 3. a copy of RMC’s Code of Conduct required by Section III.B.1; 4. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG upon request); 5. a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG upon request); 6. the following information regarding each type of training required by Section III.C: a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request. 7. a description of the Disclosure Program required by Section III.E; 8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between RMC and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to RMC; 9. a description of the process by which RMC fulfills the requirements of Section III.F regarding Ineligible Persons; 10. a list of all of RMC’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which RMC currently submits claims; 11. a description of RMC’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and 12. the certifications required by Section V.C.

Implementation Report. Within 120 150 days after the Effective Date, RMC Pediatrix shall submit a written report to the OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;; Pediatrix Medical Group, Inc. Corporate Integrity Agreement 2. the names and positions of the members of the Compliance Committee required by Section III.A; 3. a copy of RMCPediatrix’s Code of Conduct required by Section III.B.1; 4. a summary of all Policies and Procedures required by Section III.B.2; 5. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG upon request); 5. a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG OIG, upon request); 6. the following information regarding each type of training required by Section III.C: a. a description of such training, including a summary of the topics covered, the length of sessions, sessions and a schedule of training sessions; and; b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG OIG, upon request. 7. a description of the Disclosure Program required by Section III.E; 8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between RMC Pediatrix and the IRO; and (ed) the proposed start and completion dates of the Claims Review and Unallowable Cost Review; 9. a certification from the IRO regarding its professional independence and and/or objectivity with respect to RMC;Pediatrix; Pediatrix Medical Group, Inc. Corporate Integrity Agreement 910. a description of the process by which RMC Pediatrix fulfills the requirements of Section III.F regarding Ineligible Persons; 1011. the name, title, and responsibilities of any person who is determined to be an Ineligible Person under Section III.F; the actions taken in response to the screening and removal obligations set forth in Section III.F; and the actions taken to identify, quantify, and repay any overpayments to Federal health care programs relating to items or services furnished, ordered or prescribed by an Ineligible Person; 12. a list of all of RMCPediatrix’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program Provider number(s), provider number identification number(s), and/or supplier number(s); and the name and address of each Medicare and Medicaid state Medicaid program contractor agency to which RMC Pediatrix currently submits claims; 1113. a description of RMCPediatrix’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and 12. the certifications required by Section V.C.

Implementation Report. Within 120 150 days after the Effective Date, RMC Biovail shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 1. the name, address, phone number, and position description of the Chief Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Chief Compliance Officer may have; 2. the names and positions of the members of the U.S. Healthcare Compliance Policy Committee required by Section III.A; 3. a copy of RMCBiovail’s Code of Conduct required by Section III.B.1; 4. a copy of all Policies and Procedures required by Section III.B.2; 5. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG upon request); 5. a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG OIG, upon request); 6. the following information regarding each type of training required by Section III.C: a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG OIG, upon request. 7. a description of the Disclosure Program required by Section III.E; 8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; and (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between RMC Biovail and the IRO; and (e) ; 8. a certification from the IRO regarding its professional independence and objectivity with respect to RMCBiovail; 9. a description of the Disclosure Program required by Section III.E; 10. a description of the process by which RMC Biovail fulfills the requirements of Section III.F regarding Ineligible Persons; 1011. the name, title, and responsibilities of any person who is determined to be an Ineligible Person under Section III.F; the actions taken in response to the screening and removal obligations set forth in Section III.F; and the actions taken in response to the screening and removal obligations set forth in Section III.F; 12. a list of all of RMCBiovail’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program Federal health care provider number and/or or supplier number(s) (if applicable); , and the name and address of each Medicare and state Medicaid Federal health care program contractor to which RMC Biovail currently submits claimsclaims (if applicable); 1113. a description of RMCBiovail’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and 1214. the certifications required by Section V.C.

Implementation Report. Within 120 days after the Effective Date, RMC PHC shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 2. the names and positions of the members of the Compliance Committee required by Section III.A; 3. a copy of RMCPHC’s Code of Conduct required by Section III.B.1; 4. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request); 5. a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG upon request); 6. the following information regarding each type of training required by Section III.C: a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and; b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy ; and c. with respect to active medical staff members, the number and percentage who completed the training, the type of all training materials and the documentation supporting this information shall be made available date received, and a description of PHC’s efforts to OIG upon requestencourage medical staff members to complete the training. 7. a description of (a) the Focus Arrangements Tracking System required by Section III.D.1.a, (b) the internal review and approval process required by Section III.D.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.D.1; 8. a description of the Disclosure Program required by Section III.EIII.F; 8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between RMC and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to RMC; 9. a description of the process by which RMC fulfills the requirements of Section III.F regarding Ineligible Persons; 10. a list of all of RMC’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which RMC currently submits claims; 11. a description of RMC’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and 12. the certifications required by Section V.C.

Implementation Report. Within 120 days after the Effective Date, RMC Medicus shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 2. the names and positions of the Board members who are responsible for satisfying the Board of the Compliance Committee required by Directors compliance obligations described in Section III.AIII.A.3; 3. a copy of RMCMedicus’s Code of Conduct required by Section III.B.1; 4. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG upon request); 5. a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG upon request); 6. the following information regarding each type of training required by Section III.C: a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request. 7. a description of the Disclosure Program required by Section III.E; 8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between RMC Medicus and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to RMCMedicus; 9. a description of the process by which RMC Medicus fulfills the requirements of Section III.F regarding Ineligible Persons; 10. a list of all of RMCMedicus’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which RMC Medicus currently submits claims; 11. a description of RMCMedicus’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and 12. the certifications required by Section V.C.

Implementation Report. Within 120 days after the Effective Date, RMC Maximus shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 2. the names and positions of the members of the Compliance Committee required by Section III.A; 3. a copy of RMC’s Maximus’ Code of Conduct required by Section III.B.1; 4. a copy of all Policies and Procedures required by Section III.B.2; 5. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1III.B. 1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG upon request); 5. a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG OIG, upon request); 6. the following information regarding each type of training required by Section III.C: a. a description of such training, including a summary of the topics covered, the length of sessions, sessions and a schedule of training sessions; and; b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG OIG, upon request. 7. a description of the Disclosure Program required by Section III.E; 8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between RMC and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to RMC; 9. a description of the process by which RMC Maximus fulfills the requirements of Section III.F regarding Ineligible Persons; 9. the name, title, and responsibilities of any person who is determined to be an Ineligible Person under Section III.F; the actions taken in response to the screening and removal obligations set forth in Section III.F; and the actions taken to notify the State or governmental entity for which the ineligible person performed work on behalf of Maximus; 10. a list of all of RMC’s Maximus’ locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which RMC currently submits claims; 11. a description of RMC’s Maximus’ corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and 12. the certifications required by Section V.C.

Implementation Report. Within 120 150 days after the Effective Date, RMC Boston Scientific shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:: Boston Scientific Corp. Corporate Integrity Agreement 1. the name, address, phone number, and position description of the Chief Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Chief Compliance Officer may have; 2. the names and positions of the members of the Global Compliance Steering Committee required by Section III.A; 3. a copy of RMCBoston Scientific’s Code of Conduct required by Section III.B.1III.B.I and a copy of the letter (including all attachments) required by Sections III.B.2 sent to each party employing Third Party Personnel; (b) a list of all such existing Third Party Personnel agreements; and (c) a description of the Third Party Personnel entities’ response to Boston Scientific’s letter; 4. a copy of all Policies and Procedures required by Section III.B.3; 5. the number of individuals Covered Persons required to complete the Code of Conduct certification required by Section III.B.1III.▇.▇, the percentage of individuals Covered Persons who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG upon request); 5. a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG OIG, upon request); 6. the following information regarding each type of training required by Section III.C: a. a description of such training, including a summary of the topics covered, the length of sessions, and for in-person training, a schedule of training sessions; and; b. the number of individuals Covered Persons required to be trained, percentage of individuals Covered Persons actually trained, and an explanation of any exceptions. ; and c. the percentage of Third Party Personnel who do and do not attend General and/or Arrangements Training (as referenced in Section III.C.) A copy of all training materials and the documentation supporting this information shall be made available to OIG OIG, upon request.. Boston Scientific Corp. Corporate Integrity Agreement 7. a description of the Disclosure Program required by Section III.E; 8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; and (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between RMC Boston Scientific and the IRO; and (e) ; 8. a certification from the IRO 1RO regarding its professional independence and objectivity with respect to RMCBoston Scientific; 9. a description of the process by which RMC fulfills the requirements of Section III.F regarding Ineligible Persons; 10. a list of all of RMC’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which RMC currently submits claims; 11. a description of RMC’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and 12. the certifications required by Section V.C.

Implementation Report. Within 120 days after the Effective Date, RMC Kai Heart shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 2. the names and positions of the members of the Compliance Committee required by Section III.A; 3. a copy of RMCKai Heart’s Code of Conduct required by Section III.B.1; 4. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG upon request); 5. a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG upon request); 6. the following information regarding each type of training required by Section III.C: a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and; b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request. 7. a description of the Disclosure Program required by Section III.E; 8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between RMC Kai Heart and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to RMCKai Heart; 9. a description of the process by which RMC ▇▇▇ ▇▇▇▇▇ fulfills the requirements of Section III.F regarding Ineligible Persons; 10. a list of all of RMCKai Heart’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which RMC Kai Heart currently submits claims; 11. a description of RMCKai Heart’s corporate structure, including identification of any and all individual owners, any parent and sister companies, subsidiaries, and their respective lines of business; and 12. the certifications required by Section V.C.

Implementation Report. Within 120 150 days after the Effective Date, RMC Gambro shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 2. the names and positions of the members of the Compliance Committee required by Section III.A; 3. a certification that each clinic has a CCL in place, as required by Section III.A; 4. a copy of RMCGambro’s Code Standards of Business Conduct required by Section III.B.1; 45. a copy of all Policies and Procedures required by Section III.B.2; 6. the number of individuals required to complete the Code Standards of Business Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG OIG, upon request); 5. a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG upon request); 67. the following information regarding each type of training required by Section III.C: a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and; b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG OIG, upon request. 78. a description of the Disclosure Program required by Section III.EIII.F; 89. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between RMC Gambro and the IRO; and (ed) the proposed start and completion dates of the Claims Review, Unallowable Cost Review, and Stat Labs Billing Review. 10. a certification from the IRO regarding its professional independence and and/or objectivity with respect to RMC;Gambro; Gambro Healthcare, Inc. Corporate Integrity Agreement 24 911. a description of the process by which RMC Gambro fulfills the requirements of Section III.F III.G regarding Ineligible Persons; 1012. the name, title, and responsibilities of any person who is determined to be an Ineligible Person under Section III.G; the actions taken in response to the screening and removal obligations set forth in Section III.G; and the actions taken to identify, quantify, and repay any overpayments to Federal health care programs relating to items or services furnished, ordered, or prescribed by an Ineligible Person; 13. a list of all of RMCGambro’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number number(s), Gambro identification number(s), and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which RMC Gambro currently submits claims; 1114. a description of RMCGambro’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and 1215. the certifications required by Section V.C.

Implementation Report. Within 120 150 days after the Effective Date, RMC T▇▇▇▇ shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 1. the namenames, addressaddresses, phone numbernumbers, and position description descriptions of the Chief Compliance Officer, Regional Compliance Officers, Hospital Compliance Officers, and Chief Medical Officer as required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 2. the name, addresses, phone numbers, and position descriptions of the Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, General Counsel, Vice President for Government Programs, and all Regional Senior Vice Presidents; 3. the names and positions of the members of the Corporate Compliance Committee and the Regional Compliance Committees required by Section III.A; 34. the names of T▇▇▇▇’▇ directors on the Quality, Compliance, and Ethics Committee of the Board of Directors required by Section III.A.7; 5. a copy of RMC’s T▇▇▇▇’▇ Code of Conduct required by Section III.B.1; 46. an index of all Policies and Procedures required by Section III.B.2; 7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals (including Excepted Physicians) who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG OIG, upon request); 5. a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG upon request); 68. the following information regarding each type of training required by Section III.C: a. a description of such training, including a summary of the topics covered, the length of sessions, sessions and a schedule of training sessions; and; b. the number of individuals required to be trained, percentage of individuals (including Excepted Physicians) actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG OIG, upon request. 79. a description of the Disclosure Program required by Section III.E; 810. the following information regarding each of the IRO(s): IROs: (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between RMC T▇▇▇▇ and the IRO; and (ed) the proposed start and completion dates of the IRO Reviews; 11. a certification from the each IRO regarding its professional independence and objectivity with respect to RMCT▇▇▇▇; 912. a description of the process by which RMC T▇▇▇▇ fulfills the requirements of Section III.F regarding Ineligible Persons; 10. a list of all of RMC’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which RMC currently submits claims; 11. a description of RMC’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and 12. the certifications required by Section V.C.

Implementation Report. Within 120 days after the Effective Date, RMC LHC shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 2. the names and positions of the members of the Compliance Committee required by Section III.A; 3. a copy of RMCLHC’s Code of Conduct and Ethics required by Section III.B.1; 4. the number of individuals required to complete the Code of Conduct and Ethics certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG upon request); 5. a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG upon request); 6. the following information regarding each type of training required by Section III.C: a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request. 7. a description of the Disclosure Program required by Section III.E; 8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between RMC LHC and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to RMCLHC; 9. a description of the process by which RMC LHC fulfills the requirements of Section III.F regarding Ineligible Persons; 10. a list of all of RMCLHC’s locations (including locations mailing addresses and mailing addressesidentification of home health facilities); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which RMC LHC currently submits claims; 11. a description of RMCLHC’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and 12. the certifications required by Section V.C.

Implementation Report. Within 120 days after the Effective Date, RMC InterMune shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 1. a copy of the letter (including all attachments) required by Section III.B sent to each entity which employs Third Party Personnel; ii) a list of all existing distribution, purchase, joint venture and/or co-marketing agreements; and iii) a description of the entities’ response to InterMune’s letter; 2. the name, address, phone number, and position description of the Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 23. the names and positions of the members of the Compliance Committee required by Section III.A; 34. a copy of RMCInterMune’s Code of Conduct required by Section III.B.1; 45. a copy of all Policies and Procedures required by Section III.B.2; 6. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG OIG, upon request); 57. a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG upon request); 6. the the, following information regarding each type of training required by Section III.C: a. a description of such training, including a summary of the topics covered, the length of sessions, sessions and a schedule of training sessions; and; b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG OIG, upon request. 78. a description of the Disclosure Program required by Section III.E; 89. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between RMC InterMune and the IRO; and (ed) the proposed start and completion dates of each Review; 10. a certification from the IRO regarding its professional independence and and/or objectivity with respect to RMCInterMune; 9. a description of the process by which RMC fulfills the requirements of Section III.F regarding Ineligible Persons; 10. a list of all of RMC’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which RMC currently submits claims; 11. a description of RMC’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and 12. the certifications required by Section V.C.

Implementation Report. Within 120 150 days after the Effective Date, RMC Gambro shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 2. the names and positions of the members of the Compliance Committee required by Section III.A; 3. a certification that each clinic has a CCL in place, as required by Section III.A; 4. a copy of RMCGambro’s Code Standards of Business Conduct required by Section III.B.1; 45. a copy of all Policies and Procedures required by Section III.B.2; 6. the number of individuals required to complete the Code Standards of Business Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG OIG, upon request); 5. a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG upon request); 67. the following information regarding each type of training required by Section III.C: a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and; b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG OIG, upon request. 78. a description of the Disclosure Program required by Section III.EIII.F; 89. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between RMC Gambro and the IRO; and (ed) the proposed start and completion dates of the Claims Review, Unallowable Cost Review, and Stat Labs Billing Review. 10. a certification from the IRO regarding its professional independence and and/or objectivity with respect to RMC;Gambro; Gambro Healthcare, Inc. Corporate Integrity Agreement 911. a description of the process by which RMC Gambro fulfills the requirements of Section III.F III.G regarding Ineligible Persons; 1012. the name, title, and responsibilities of any person who is determined to be an Ineligible Person under Section III.G; the actions taken in response to the screening and removal obligations set forth in Section III.G; and the actions taken to identify, quantify, and repay any overpayments to Federal health care programs relating to items or services furnished, ordered, or prescribed by an Ineligible Person; 13. a list of all of RMCGambro’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number number(s), Gambro identification number(s), and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which RMC Gambro currently submits claims; 1114. a description of RMCGambro’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and 1215. the certifications required by Section V.C.

Implementation Report. Within 120 150 days after the Effective Date, RMC CVS Caremark shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 1. the name, address, phone number, and position description of the Compliance Officer required by Section III.AIII.A.1, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 2. the names and positions of the members of the Compliance Committee required by Section III.AIII.A.2; 3. the names of the members of the full Board of Directors, as well as the Audit Committee (or other authorized subcommittee) members who are responsible for satisfying the compliance obligations described in Section III.A.3; 4. a copy of RMCCVS Caremark’s Code of Conduct required by Section III.B.1; 45. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request); 56. a summary or copies of all Policies and Procedures required by Section III.B III.B.2 (copies of the Policies and Procedures shall be made available to OIG upon request); 67. the following information regarding the notification and each type of training required by Section III.C: a. a description of the notification procedures required under Section III.C.1, the number of individuals required to be notified, the percentage of individuals actually notified, and an explanation of any exceptions; b. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and b. c. the number of individuals required to be trained, the percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request. 78. a description of the Disclosure Program required by Section III.E; 89. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between RMC CVS Caremark and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to RMCCVS Caremark; 910. a description of the process by which RMC CVS Caremark fulfills the requirements of Section III.F regarding Ineligible Persons; 1011. a list of all states in which the PBM Operations do business, the number of RMC’s PBM Operations locations (including locations in each state, and mailing addresses); the corresponding name any names other than CVS Caremark under which each location is any of the PBM Operations locations are doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which RMC currently submits claims; 1112. a description of RMCCVS Caremark’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and 12. the certifications required by Section V.C.

Implementation Report. Within 120 days after the Effective Date, RMC Sound shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 2. the names and positions of the members of the Compliance Committee required by Section III.A; 3. a copy of RMCSound’s Code of Conduct required by Section III.B.1; 4. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG upon request); 5. a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG upon request); 6. the following information regarding each type of training required by Section III.C: a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request. 7. a description of the Disclosure Program required by Section III.E; 8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between RMC Sound and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to RMCSound; 9. a description of the process by which RMC Sound fulfills the requirements of Section III.F regarding Ineligible Persons; 10. a list of all of RMCSound’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which RMC Sound currently submits claims; 11. a description list of RMCall Sound’s corporate structureexisting Agreements to provide physician services that may be reimbursed by Federal health care programs, including identification the contracting party’s address, business unit or location, phone number, fax number, the party’s location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name and address of any parent each Medicare and sister companies, subsidiaries, and their respective lines of business; and 12. state Medicaid program contractor to which Sound submits claims pursuant to the certifications required by Section V.C.Agreement.

Implementation Report. Within 120 150 days after the Effective Date, RMC Odyssey shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 2. the names and positions of the members of the Compliance Committee required by Section III.A; 3. a copy of RMCOdyssey’s Code of Conduct required by Section III.B.1; 4. a copy of all Policies and Procedures required by Section III.B.2; 5. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG upon request); 5. a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG OIG, upon request); 6. the following information regarding each type of training required by Section III.C: a. a description of such training, including a summary of the topics covered, the length of sessions, sessions and a schedule of training sessions; and; b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG OIG, upon request. 7. a description of the Disclosure Program required by Section III.E; 8. the following information regarding the IRO(sIVO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between RMC Odyssey and the IROIVO; and (ed) the proposed start and completion dates of the IVO Verification Review of Clinical Protocol Internal Reviews and of Unallowable Costs. 9. a certification from the IRO IVO regarding its professional independence and and/or objectivity with respect to RMCOdyssey; 910. a description of the process by which RMC Odyssey fulfills the requirements of Section III.F regarding Ineligible Persons; 1011. the name, title, and responsibilities of any person who is determined to be an Ineligible Person under Section III.F; the actions taken in response to the screening and removal obligations set forth in Section III.F; and the actions taken to identify, quantify, and repay any Federal health care program Overpayments relating to items or services furnished, ordered or prescribed by an Ineligible Person; 12. a list of all of RMCOdyssey’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program Provider number(s), provider number identification number(s), and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which RMC Odyssey currently submits claims; 1113. a description of RMCOdyssey’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and 12. the certifications required by Section V.C.